Key result
Targeted sequencing in HCM identifies 3 novel TTN missense variants predicted to impact function.
Why the study?
Most cardiogenetic panel variants remain classified as variants of unknown significance, making in-depth supplementary studies on such vast numbers unfeasible without prioritization.
Observational (n=45)
No
In silico analysis successfully prioritized 3 novel TTN missense variants as likely function-impacting in a cohort of Romanian patients with hypertrophic cardiomyopathy, reducing the need for extensive experimental studies.
Supports computational prioritization of novel TTN variants in HCM; leaves open functional validation before clinical adoption.
Background and aim Most of detected variants in cardiogenetic panels are still classified as variants of unknown significance, requiring supplementary analyses for a definite classification. Performing further in-depth studies on such vast number of candidates is unfeasible. We sought to prioritise the novel nonsynonymous missense variants identified in titin gene (TTN) in a cohort of Romanian index cases with hypertrophic cardiomyopathy (HCM). Methods 45 unrelated probands with HCM were screened by targeted next generation sequencing (NGS) covering all TTN exons. A stepwise strategy was used to select and prioritize the candidate variants for subsequent investigation. Results Using rigorous bioinformatic filtering, 7 novel TTN nonsynonymous missense variants were identified and were the subject of in silico sequential analysis. 4 of the 7 variants were predicted to be possibly pathogenic by the Mendelian Clinically Applicable Pathogenicity (M-CAP) algorithm. Of these, three sequence variants (c.30392G>T, c.2518G>T, and c.49G>T) were also predicted to be destabilizing according to the second computational tool (TITINdb) and were designated as likely function-impacting. Conclusions Herein we presented our strategy to hand-pick the novel TTN missense variants to be considered for further experimental studies. By applying various in silico tools, we restricted the list of sequence variants to be investigated to those most likely to be disease-associated, and thus reducing the need to perform expensive and time-consuming additional studies.
No takes yet. Share an insight, caveat, or question.
Micheu et al. (2021) conducted an observational in Hypertrophic cardiomyopathy (n=45). Targeted next-generation sequencing and in silico analysis was evaluated on Identification and prioritization of novel TTN nonsynonymous missense variants. In silico analysis of targeted next-generation sequencing data from 45 patients with hypertrophic cardiomyopathy identified 3 novel TTN missense variants predicted to be likely function-impacting.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: